Sign in
Taking people in United StatesNo phase

Skin-surface spinal cord stimulation for people with spinal cord injury or cervical myelopathy

Tests the safety and practicality of spinal cord stimulation through the skin after spinal injury.

Key facts

Who runs it
Francis Farhadi
Where
Lexington, United StatesSee the site
Trial code
Registry title
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study
Status
Recruiting
People taking part
30 people, planned
Started
23 Oct 2024
Expected to end
1 Dec 2027
Type of study
Interventional, 3 groupsOne group gets an existing treatment, for comparison.
Treatments tested
  • Transcutaneous Spinal Cord Stimulation (Tc-SCS)
Record updated
7 July 2026

Who can take part

The trial is looking for adults with spinal cord damage in the neck or upper back. This can be from wear and tear (cervical myelopathy) or from an injury. It tests a skin-surface spinal cord stimulation device.

Age
18 to 80 years
Sex
All
Disease stage
Cervical myelopathy with a modified Japanese Orthopaedic Association (mJOA) score of 8-14. Or acute neck or upper-back spinal cord injury, ASIA grade A-D (judged within 72 hours of injury), injury level C2 to T12. Injured people join early in hospital or 6-24 months after injury.
Earlier treatment
People must be able to have spine surgery, or must have had it. Stimulation starts at or after 14 days from surgery.
Main reasons for not taking part
  • Other conditions affecting the arms or legs, such as peripheral neuropathy, dementia or Parkinson's disease
  • mJOA score of 15 or more, or 7 or less, or AIS grade E injury
  • Pregnancy
  • Dependence on a cardiac pacemaker, or a brain implant or skull plate
  • Taking part in another interventional spinal cord injury study or drug study
Show the full registry criteria (20)Hide the full registry criteria

Who can take part

  • Age: = 18 years and = 80 years
  • Written informed consent by patient and/or legal authorized representative (LAR)
  • No other life-threatening condition
  • No evidence of sepsis
  • No evidence of superficial skin infection at site of surgery and intervention
  • An established diagnosis of either:; cervical myelopathy with modified Japanese Orthopaedic Association score of 8-14, or; acute cervical / thoracic SCI with ASIA Impairment Scale grade A-D (as assessed within 72 hours of injury) with neurologic level of injury (NLI) from C2 to T12
  • The ability to undergo, or have had, surgical intervention. -. The ability to undergo transcutaneous intervention including study procedures in the posterior cervical or thoracic midline at or after 14 days from surgery

Who cannot take part

  • Any concomitant impairment of the upper and lower limb at baseline that could potentially confound the neurologic assessments; including but not limited to traumatic or disease conditions like brachial plexus injury, peripheral neuropathy, spinal hematoma, transverse myelitis, non-compressive myelopathy, dementia, and Parkinson's disease
  • Currently involved in another non-observational ntSCI or tSCI study, or receiving another interventional drug, that could interfere with recordings and confound adverse events
  • Brain implant, skull prosthesis, plate and screws limiting transcranial stimulation
  • Other illness (including mental disorder) that could preclude accurate medical and neurological evaluation, at discretion of the treating surgeon and/or principal investigator
  • Recent history of regular substance abuse (illicit drugs, alcohol), which in the opinion of the investigator would interfere with the subject's participation in the study
  • Any condition likely to result in the patient's death within the next 12 months
  • Cardiac pacemaker dependent, unable to undergo electrical stimulation
  • mJOA of >= 15 and <= 7, or AIS grade E tSCI at baseline assessment
  • Unable to commit to the follow-up schedule
  • Prisoner
  • Pregnancy
  • Tattoo at site of skin electrode that causes heat/pain during stimulation
  • Subjects who in the opinion of the investigator are not suitable for inclusion in the study, with reason documented

Eligibility questionnaire

From the criteria published for this trial, to help you prepare for a talk with your doctor or the study team. We do not tell you a result. Only the study team can say whether you can take part.

  • Age

This trial is currently available in United States.

  • University of Kentucky Chandler Medical CenterLexington, United StatesContact: Francis H Farhadi, MD, PhDTaking people

About the trial

What the trial wants to find out

The study will be a non-randomized, non-blinded pilot study to analyze the safety and feasibility of a non-significant risk device, transcutaneous spinal cord stimulation. The aim is to include 30 total patients, 10 patients in each of 3 groups:

Read full original descriptionShow less

1. Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy and offered surgical intervention. 2. Early tSCI screened during the hospital admission when cervical/thoracic spinal injury was diagnosed. 3. Delayed tSCI (control) screened 6-24 months after acute cervical/thoracic spinal injury.

The 3 groups in the trial

  • Non-Traumatic Spinal Cord Injury (ntSCI,) DCM - ProgressiveTreatment being tested

    Non-traumatic spinal cord injury (ntSCI) with diagnosis of degenerative cervical myelopathy (DCM) and offered surgical intervention. Prospective.

    Treatment: Transcutaneous Spinal Cord Stimulation (Tc-SCS)

  • Traumatic Spinal Cord Injury (tSCI) - Early/AcuteTreatment being tested

    Traumatic spinal cord injury (tSCI) screened during the hospital admission when cervical/thoracic spinal injury was diagnosed. 2-6 weeks after injury.

    Treatment: Transcutaneous Spinal Cord Stimulation (Tc-SCS)

  • Traumatic Spinal Cord Injury (tSCI) - ChronicExisting treatment, for comparison

    Delayed traumatic spinal cord injury (tSCI) screened 6-24 months after acute cervical/thoracic spinal injury. The use of transcutaneous spinal cord stimulation (Tc-SCS) in chronic SCI delivered in the delayed timeframe is relatively well studied, and therefore will serve as the control arm.

    Treatment: Transcutaneous Spinal Cord Stimulation (Tc-SCS)

Next steps

For your doctor

Doctor ask sheet

A PDF for your doctor: what this trial tests, who can take part, and 1 eligibility question with room for answers and notes.

Download the PDF

PDF, US Letter, 1 to 2 pages. A4 size

For the study team

Questions to ask the study team

  1. How often do I need to come in, and for how long each time?
  2. Are travel costs paid?
  3. Can I keep my own doctor?
  4. What happens if I want to stop?

Contact the study team: see the registry record → Contacts and Locations

Data and sources

Registry record
Listed on ClinicalTrials.gov.How to verify a trial in the registry
Official title
Evaluating Safety and Feasibility of Transcutaneous Spinal Cord Stimulation Following Traumatic and Non-Traumatic Spinal Cord Injury: A Pilot Study
Plain-language title
Skin-surface spinal cord stimulation for people with spinal cord injury or cervical myelopathyGenerated from the registry record. The registry title is the official one.
AI summary
From the trial's eligibility criteria. Read by machine on 14 November 2026.
Criteria questions
Built from NCT06520020, who can take part
Record updated
7 July 2026